#AlzheimerDisease is an active hashtag on Bluesky. In the last 30 days, 7 people shared 15 posts with it — around 1 a day. Activity is down 50% versus the previous week, peaking on Jul 13 with 3 posts.

Posts with #AlzheimerDisease

JAMA

@jama.com

5 months ago

💬 Viewpoint: FDA-cleared blood tests for #AlzheimerDisease improve diagnostic access but may lead to misdiagnosis, disparities, and legal or psychological harms without careful risk mitigation. ja.ma/4sdBT1r

JAMA viewpoint article published online January 22, 2026, titled "Blood-Based Biomarkers for Alzheimer Disease Preventing Unintended Consequences" by Heather E. Whitson, Nicole R. Fowler, and Michelle M. Mielke.

1 2 12

JAMA

@jama.com

6 months ago

JAMA viewpoint on blood-based biomarkers for Alzheimer's disease, preventing unintended consequences. Article by Heather E. Whitson, Nicole R. Fowler, and Michelle M. Mielke, published online January 22, 2026.

0 3 12

JAMA

@jama.com

6 months ago

📊 Research Summary: Valacyclovir did not improve cognition or function in patients with early symptomatic #AlzheimerDisease with HSV seropositivity and is not supported for use in this population. ja.ma/4kCz3Ad

JAMA Research Summary: Valacyclovir Treatment of Early Symptomatic Alzheimer Disease. Key findings: cognitive impairment worsened more in the valacyclovir group. Least-squares mean change at 78 weeks: Valacyclovir@10.86, Placebo@6.92.

1 2 10

JAMA

@jama.com

7 months ago

Valacyclovir was associated with greater cognitive decline and did not improve disease markers in patients with symptomatic #AlzheimerDisease and HSV seropositivity. ja.ma/4qydeE1

JAMA infographic: study on valacyclovir for Alzheimer's. Question: Can valacyclovir provide benefit? Conclusion: Not efficacious. Population: 66 women, 54 men, mean age 71.4. Intervention: 120 patients randomized to valacyclovir or placebo. Findings: Valacyclovir worsened cognition vs. placebo.

0 3 9

JAMA

@jama.com

29 days ago

💬 Viewpoint: Earlier #AlzheimerDisease diagnosis with biomarkers can prompt urgent assisted dying inquiries, highlighting the importance of psychosocial counseling and longitudinal decision-making support. ja.ma/4gNtyz9

JAMA Viewpoint article: 'Alzheimer Disease Biomarkers and Assisted Dying: When Diagnosis Becomes a Deadline.' Authors include Stanley Lyndon, Lauren M. Behlke, Juan Carlos Urizar, et al. Published online July 9, 2026. The page shows navigation options.

0 1 8

JAMA

@jama.com

about 2 months ago

💬 Perspective: Monoclonal antibodies for #AlzheimerDisease clear brain amyloid-β and modestly slow cognitive decline in early stages, supporting a causal role but with clinically limited impact and risk for imaging abnormalities. ja.ma/4ehhqog

JAMA Perspective article titled 'Stopping Alzheimer Disease 50 Years of Progress' by John K. Hsiao, MD, published online June 22, 2026. The text discusses the history, challenges, and research developments in Alzheimer's disease over 50 years.

0 1 7

JAMA Network Open

@jamanetworkopen.com

6 days ago

Adding plasma #AlzheimerDisease biomarker data, especially amyloid-β 1-40, to clinical factors and the Montreal Cognitive Assessment modestly improved postoperative #Delirium risk estimation after #CardiacSurgery. ja.ma/4xlPdn3

ROC curve graph of Sensitivity vs. 1-Specificity comparing 4 models: Biomarker only, Clinical variables only, Biomarker controlled for clinical variables, and Biomarker, clinical variables, & MoCA. The MoCA combination (green) shows the best performance; "Biomarker only" (blue) shows the lowest.

0 0 1

JAMA

@jama.com

26 days ago

Presented at #AAIC26: #Amyloid clearance was most efficient in gyral crests, not sulcal depths, and correlated locally with reduced #tau #pathology and #neurodegeneration after aducanumab therapy in #AlzheimerDisease. ja.ma/4yiSchb

JAMA Figure 2: Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease. Panels A-C display beta-amyloid plaques & clearance in brain tissue; D-F show phosphorylated tau pathology, reactive microglia & astrocytes at various magnifications. Published July 12, 2026.

0 2 6

JAMA

@jama.com

7 months ago

A JAMA article titled "Blood-Based Biomarkers for Alzheimer Disease Preventing Unintended Consequences" by Heather E. Whitson, Nicole R. Fowler, and Michelle M. Mielke, published online January 22, 2026.

0 1 6

JAMA

@jama.com

8 months ago

Valacyclovir was associated with greater cognitive decline and did not improve disease markers in patients with symptomatic #AlzheimerDisease and HSV seropositivity. ja.ma/4rYMRZe

1 1 6

Flavie Strappazzon

@flaviestrappazzon.bsky.social

over 1 year ago

I am extremely pleased to share our latest work on the efficacy of the NDP52GE variant in combating the accumulation of pathological forms of Tau and which is emerging as a protective factor against #AlzheimerDisease. #autophagy rdcu.be/ehPVj Kudos to Anna who drove this project! « Ad maiora ... »

rdcu.be

A variant of the autophagic receptor NDP52 counteracts phospho-TAU accumulation and emerges as a protective factor for Alzheimer’s disease

Cell Death & Disease - A variant of the autophagic receptor NDP52 counteracts phospho-TAU accumulation and emerges as a protective factor for Alzheimer’s disease

1 1 6

JAMA

@jama.com

about 1 month ago

The first FDA-cleared blood test for #AlzheimerDisease biomarkers, intended for use in specialty clinics for adults ≥50 with symptoms, may produce more false positive or indeterminate results in real-world practice than anticipated. 🎧 Listen now: ja.ma/4p66Lkc